EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

Aroog Khaliq, William Wesson, Emerson Logan, Carine Tabak, Muhammad Umair Mushtaq, Tara Lin, Joaquina Baranda, Leyla Shune, Al-Ola Abdallah, Joseph McGuirk, Mehdi Hamadani, Nausheen Ahmed

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2024.05.022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Aroog Khaliq und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Kansas School of Medicine, Kansas City, KS. Hauptthemen laut MEDLINE: Authorship, Lymphoma, Antigens, CD19, Clinical Trials as Topic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Existing literature suggests that women are significantly underrepresented in the field of hematology-oncology. Women make up 35.6% of hematologists and data on females as site investigators for pivotal trials and authors in publications of pivotal trials in hematologic malignancies, specifically in the novel niche of Chimeric antigen receptor T cell (CAR-T), is sparse. METHODS: We examined the proportion of women in pivotal trials, screening a total of 2180 studies from PubMed using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. 2180 initially searched records were filtered by date (2017-2023) and clinical trial status, yielding 149 records. Following a manual review, we included 15 studies that led to the approval of or anticipated approval of CD19 and BCMA CAR-T therapies in lymphoid and plasma cell malignancies. We examined overall number of female authors, number of lead female authors, and ratio of all authors to female authors in the 15 trials, which were all high impact, cited on average 1314 times. RESULTS: Of the 436 authors assessed, 132 were female, correlating to 29.5% female authorship. The only study with female authorship >50% was ELIANA, a 2017 pediatric study. 7 of the 15 studies had female lead authors; notably, 6 out of 7 of these studies were published in 2021 or later. CONCLUSION: In conclusion, our data suggests gender iniquities for female investigators exist in the field of immune effector cell therapy. We suggest further investigation and strategies to decrease gendered authorship disparities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AuthorshipLymphomaAntigens, CD19Clinical Trials as TopicMultiple MyelomaImmunotherapy, AdoptiveHumansFemaleMaleB-Cell Maturation Antigen

Stichwörter der Autor:innen

CAR-TClinical trialsGenderGender disparityImmunotherapies

Substanzen

Antigens, CD19B-Cell Maturation Antigen

Autor:innen und Institutionen

  • Department of Medicine, University of Kansas School of Medicine, Kansas City, KS.
  • Division of Hematologic Malignances and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; US Myeloma Innovations Research Collaborative, Westwood, KS.
  • Division of Hematologic Malignances and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS.
  • Department of Medicine, University of Kansas Medical Center, Kansas City, KS.
  • Division of Hematologic Malignances and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Department of Medicine, University of…
  • Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.

Förderung

  • National Institutes of Health

Zitieren

APA

Khaliq, A., Wesson, W., Logan, E., Tabak, C., Mushtaq, M. U., Lin, T., Baranda, J., Shune, L., Abdallah, A. O., McGuirk, J., Hamadani, M., & Ahmed, N. (2024). The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.05.022

Vancouver

Khaliq A, Wesson W, Logan E, Tabak C, Mushtaq MU, Lin T, et al. The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.05.022

BibTeX
@article{Khaliq2024,
  author = {Khaliq, Aroog and Wesson, William and Logan, Emerson and Tabak, Carine and Mushtaq, Muhammad Umair and Lin, Tara and Baranda, Joaquina and Shune, Leyla and Abdallah, Al-Ola and McGuirk, Joseph and Hamadani, Mehdi and Ahmed, Nausheen},
  title = {The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2024.05.022}
}
Kostenlos starten →